Lysogene Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;padding-top: 25px;;'>LY</div>
In this post, we will digest Lysogene. We will cover the possibilities of making Lysogene into a steady grower in August. Lysogene chance of bankruptcy is under 66 percent. Assuming the 30 trading days horizon, Lysogene is expected to generate 1.36 times less return on investment than the market. In addition to that, the company is 1.02 times more volatile than its market benchmark. It trades about 0.13 of its total potential returns per unit of risk. The market is currently generating roughly 0.18 per unit of volatility. We estimate Lysogene as currently undervalued. The real value is approaching 4.68 per share. Lysogene secures a last-minute Real Value of $4.68 per share. The latest price of the firm is $4.11. At this time, the firm appears to be undervalued. Our model forecasts the value of Lysogene from analyzing the firm fundamentals such as shares outstanding of 16.35 M, return on equity of (92.11) %, and profit margin of (25.91) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point asset prices and their ongoing real values will merge together.
Published over a month ago
View all stories for Lysogene | View All Stories
Is it time to opt out of Lysogene?
The firm classifies itself under Healthcare sector and is part of Biotechnology industry. Lysogene has a current ratio of 1.06, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. We provide buy, hold, or sell recommendation to complement the last-minute expert consensus on Lysogene. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.

How Lysogene utilizes its cash?

To perform a cash flow analysis of Lysogene, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Lysogene is receiving and how much cash it distributes out in a given period. The Lysogene cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

What is driving Lysogene Investor Appetite?

The latest bullish price patterns experienced by current Lysogene shareholders may encourage investors to take a closer look at the firm as it closed today at a share price of 4.11 on slow start in trading volume. The company management have been very successful with rebalancing the firm assets at opportune times to take advantage of market volatility in June. The stock standard deviation of daily returns for 30 days investing horizon is currently 2.13. The current volatility is consistent with the ongoing market swings in June 2020 as well as with Lysogene unsystematic, company-specific events.

Will Lysogene shareholders exit after the next dip?

Ongoing Information Ratio is up to -0.03. Price may dip again. Lysogene exhibits very low volatility with skewness of 8.12 and kurtosis of 66.0. However, we advise investors to further study Lysogene technical indicators to make sure all market info is available and is reliable.

Our Final Take On Lysogene

While many of the other players under biotechnology industry are still a little expensive, even after the recent corrections, Lysogene may offer a potential longer-term growth to investors. All in all, as of 2nd of July 2020, our overall 30 days buy vs. sell advice on the firm is Strong Buy. We believe Lysogene is undervalued with quite high odds of financial distress for the next two years. With an optimistic outlook on your 30 days horizon, it may be a good time to take up new shares of Lysogene or increase your existing holdings in the OTC Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Lysogene.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Lysogene. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page